Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023 – ResearchAndMarkets.com

May 16, 2023 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023” report has been added to ResearchAndMarkets.com’s offering.

Report Highlights:

  • Global Market Yearly and Quarterly Sales Insight (2018 till Q1’2023)
  • Global Market Forecast Till 2028
  • Global and Regional Sales Insights By Drugs (2018 till Q1’2023)
  • Approved Bispecific Antibodies: 9
  • Insight On Bispecific Antibodies In Clinical Trials: > 700 Bispecific Antibodies
  • Global Bispecific Antibodies Clinical Trials By Company, Indication and Phase
  • Fast Track Approval, Orphan Designation, and Priority Status Insights
  • Approved Bispecific Antibodies Pricing and Dosage Analysis
  • Competitive Landscape: Top 50 Companies Developing Bispecific Antibodies

The introduction of antibody-based therapeutics has been a game changer in the field of cancer therapy. Monoclonal antibodies have been around for decades and still, their role has been ever so significant. However, with the rising clinically unmet medical needs, current efforts are focused on developing advanced forms of these biologics. The continued expansion in research and development of antibody biologics has brought in the era of bispecific antibodies.

These bispecific antibodies are capable of engaging or targeting two distinct targets and therefore are able to simultaneously perform multiple actions including; directing the immune cells to tumor cells, blocking two different pathways simultaneously, and delivering cytotoxic payloads. Over the past few decades, there have been a number of difficulties with the production of bispecific antibodies; nevertheless, they have shown great potential as promising cancer therapeutics.

Bispecific antibodies are fast-growing engineered biologics that have significantly improved significant unmet medical needs. The fast approval of Columvi showed the urgency of this particular bispecific product. With the expansion of the global pharmaceutical industry developing a robust clinical pipeline for the research and development of bispecific antibodies, there are numerous candidates currently undergoing clinical trials while several are being tested in preclinical studies.

The range of therapeutics has been increasing, similar to the rising demand for innovation in the pharmaceutical industry. This increase in the growing expansion of antibodies can be due to the increasing regulatory approvals. Recently, Roche’s Glofitamab (Columvi), a bispecific T cell engager molecule (BiTE) was approved by Health Canada for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL).

The approval was based on the clinical study called NP30179 where more than 30% of patients who received Glofitamab showed cancer disappearance. This marked the first-ever approval for this CD20 x CD3 targeting bispecific antibody. . By simultaneously engaging the CD20 receptor on B cells and CD3 on the T cells, Glofitamab facilitates the development of an immunological synapse with the following proliferation of T-cells and their activation, cytokine secretion, and release of cytolytic proteins that results in the killing of tumor cells which express CD20 surface receptor.

There are several factors that are driving the growth of the bispecific antibody market which include; improved regulatory framework, persistent clinical trials having promising results, and increasing investment with active assets. As the global pharmaceutical industry realizes the commercial as well as the therapeutic potential of bispecific antibodies, we can expect an increase in the number of possible clinical candidates in the coming years.

Moreover, as the industry develops, there is also a growing number of competitors. A few years ago, there were only a handful of pharmaceutical players in the bispecific antibody market, however, now there are multiple stakeholders that are continuously working to develop novel bispecific antibodies. Furthermore, with eagerness to enter the market, several companies have also chosen the road to collaboration.

Key Topics Covered:

1. Introduction to Bispecific Antibody

2. Commercially Approved Bispecific Antibodies Insight: Company, Indication, Location & MOA

3. Global & Regional Bispecific Antibody Market Outlook (2018 till Q1’2023)

4. Global Bispecific Antibody Market Trends

5. Blincyto: 1st Approved Bispecific Antibody

6. Hemlibra: 2nd Approved Bispecific Antibody

7. Rybrevant: 3rd Approved Bispecific Antibody

8. Kimmtrak: 4th Approved Bispecific Antibody

9. Vabysmo: 5th Approved Bispecific Antibody

10. Lunsumio: 6th Approved Bispecific Antibody

11. Cadonilimab: 7th Approved Bispecific Antibody

12. Tecvayli: 8th Approved Bispecific Antibody

13. Columvi: 9th Approved Bispecific Antibody

14. Global Bispecific Antibodies Clinical Pipeline Overview

15. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

4. Global Bispecific Antibody Market Trends

5. Blincyto: 1st Approved Bispecific Antibody

6. Hemlibra: 2nd Approved Bispecific Antibody

7. Rybrevant: 3rd Approved Bispecific Antibody

8. Kimmtrak: 4th Approved Bispecific Antibody

9. Vabysmo: 5th Approved Bispecific Antibody

10. Lunsumio: 6th Approved Bispecific Antibody

11. Cadonilimab: 7th Approved Bispecific Antibody

12. Tecvayli: 8th Approved Bispecific Antibody

13. Columvi: 9th Approved Bispecific Antibody

14. Global Bispecific Antibodies Clinical Pipeline Overview

15. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

16. Marketed Bispecific Antibodies Clinical Insight

17. Competitive Landscape

17.1 ABL Bio

17.2 Abzyme Therapeutics

17.3 Affimed Therapeutics

17.4 Akeso Biopharma

17.5 Alligator Bioscience

17.6 Amgen

17.7 Antibody Therapeutics

17.8 APITBIO

17.9 Aptevo Therapeutics

17.10 Astellas Pharma

17.11 AstraZeneca

17.12 BioAtla

17.13 Biosion

17.14 Biotheus

17.15 BJ Bioscience

17.16 EpimAb Biotherapeutics

17.17 FutureGen Biopharmaceutical

17.18 Genentech

17.19 Genmab

17.20 Gensun Biopharma

17.21 Harbour BioMed

17.22 IGM Biosciences

17.23 I-MAB Biopharma

17.24 ImmuneOnco Biopharma

17.25 ImmunoPrecise Antibodies

17.26 Innovent Biologics

17.27 Invenra

17.28 Janssen Biotech

17.29 Janssen Research & Development

17.30 Kenjockety Biotechnology

17.31 L and L Biopharma

17.32 LaNova Medicines Limited

17.33 Light Chain Bioscience

17.34 Linton Pharm

17.35 Lyvgen Biopharma

17.36 MacroGenics

17.37 Merus

17.38 NovaRock Biotherapeutics

17.39 OriCell Therapeutics

17.40 Pfizer

17.41 Phanes Therapeutics

17.42 Prestige BioPharma

17.43 Regeneron Pharmaceuticals

17.44 Revitope

17.45 Roche

17.46 Virtuoso Therapeutics

17.47 Xencor

17.48 Y-Biologics

17.49 Zhejiang Shimai Pharmaceutical

17.50 Zymeworks

For more information about this report visit https://www.researchandmarkets.com/r/mqwh9

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900